 | • レポートコード：MRC2-11QY00179 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は化学療法好中球減少症治療のグローバル市場について調査・分析したレポートです。種類別（抗生物質療法、コロニー刺激因子療法、顆粒球輸血、脾臓摘出術、その他）市場規模、用途別（病院、外来外科センター、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別化学療法好中球減少症治療の競争状況、市場シェア ・世界の化学療法好中球減少症治療市場：種類別市場規模 2015年-2020年（抗生物質療法、コロニー刺激因子療法、顆粒球輸血、脾臓摘出術、その他） ・世界の化学療法好中球減少症治療市場：種類別市場規模予測 2021年-2026年（抗生物質療法、コロニー刺激因子療法、顆粒球輸血、脾臓摘出術、その他） ・世界の化学療法好中球減少症治療市場：用途別市場規模 2015年-2020年（病院、外来外科センター、診断センター） ・世界の化学療法好中球減少症治療市場：用途別市場規模予測 2021年-2026年（病院、外来外科センター、診断センター） ・北米の化学療法好中球減少症治療市場分析：米国、カナダ ・ヨーロッパの化学療法好中球減少症治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの化学療法好中球減少症治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の化学療法好中球減少症治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの化学療法好中球減少症治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Amgen、Sanofi、Novartis AG、Baxter International、Teva Pharmaceuticals Industries、Apotex、Dr. Reddy’s Laboratory、Biogenomics Limited、Ligand Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Chemotherapy-Induced Neutropenia Treatment Market
The global Chemotherapy-Induced Neutropenia Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Chemotherapy-Induced Neutropenia Treatment Scope and Market Size
Chemotherapy-Induced Neutropenia Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy-Induced Neutropenia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Chemotherapy-Induced Neutropenia Treatment market is segmented into
Antibiotic Therapy
Colony-Stimulating Factor Therapy
Granulocyte Transfusion
Splenectomy Procedure
Others
Segment by Application, the Chemotherapy-Induced Neutropenia Treatment market is segmented into
Hospitals
Ambulatory Surgical Center
Diagnostic Centers
Regional and Country-level Analysis
The Chemotherapy-Induced Neutropenia Treatment market is analysed and market size information is provided by regions (countries).
The key regions covered in the Chemotherapy-Induced Neutropenia Treatment market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Chemotherapy-Induced Neutropenia Treatment Market Share Analysis
Chemotherapy-Induced Neutropenia Treatment market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Chemotherapy-Induced Neutropenia Treatment business, the date to enter into the Chemotherapy-Induced Neutropenia Treatment market, Chemotherapy-Induced Neutropenia Treatment product introduction, recent developments, etc.
The major vendors covered:
Amgen
Sanofi
Novartis AG
Baxter International
Teva Pharmaceuticals Industries
Apotex
Dr. Reddy’s Laboratory
Biogenomics Limited
Ligand Pharmaceuticals
1 Study Coverage
1.1 Chemotherapy-Induced Neutropenia Treatment Product Introduction
1.2 Market Segments
1.3 Key Chemotherapy-Induced Neutropenia Treatment Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size Growth Rate by Type
1.4.2 Antibiotic Therapy
1.4.3 Colony-Stimulating Factor Therapy
1.4.4 Granulocyte Transfusion
1.4.5 Splenectomy Procedure
1.4.6 Others
1.5 Market by Application
1.5.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Center
1.5.4 Diagnostic Centers
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size, Estimates and Forecasts
2.1.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue 2015-2026
2.1.2 Global Chemotherapy-Induced Neutropenia Treatment Sales 2015-2026
2.2 Global Chemotherapy-Induced Neutropenia Treatment, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Chemotherapy-Induced Neutropenia Treatment Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Chemotherapy-Induced Neutropenia Treatment Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Chemotherapy-Induced Neutropenia Treatment Competitor Landscape by Players
3.1 Chemotherapy-Induced Neutropenia Treatment Sales by Manufacturers
3.1.1 Chemotherapy-Induced Neutropenia Treatment Sales by Manufacturers (2015-2020)
3.1.2 Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Manufacturers (2015-2020)
3.2 Chemotherapy-Induced Neutropenia Treatment Revenue by Manufacturers
3.2.1 Chemotherapy-Induced Neutropenia Treatment Revenue by Manufacturers (2015-2020)
3.2.2 Chemotherapy-Induced Neutropenia Treatment Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Chemotherapy-Induced Neutropenia Treatment Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Chemotherapy-Induced Neutropenia Treatment Revenue in 2019
3.2.5 Global Chemotherapy-Induced Neutropenia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Chemotherapy-Induced Neutropenia Treatment Price by Manufacturers
3.4 Chemotherapy-Induced Neutropenia Treatment Manufacturing Base Distribution, Product Types
3.4.1 Chemotherapy-Induced Neutropenia Treatment Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Chemotherapy-Induced Neutropenia Treatment Product Type
3.4.3 Date of International Manufacturers Enter into Chemotherapy-Induced Neutropenia Treatment Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size by Type (2015-2020)
4.1.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Type (2015-2020)
4.1.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Type (2015-2020)
4.1.3 Chemotherapy-Induced Neutropenia Treatment Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Type (2021-2026)
4.2.1 Global Chemotherapy-Induced Neutropenia Treatment Sales Forecast by Type (2021-2026)
4.2.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue Forecast by Type (2021-2026)
4.2.3 Chemotherapy-Induced Neutropenia Treatment Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Chemotherapy-Induced Neutropenia Treatment Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size by Application (2015-2020)
5.1.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Application (2015-2020)
5.1.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Application (2015-2020)
5.1.3 Chemotherapy-Induced Neutropenia Treatment Price by Application (2015-2020)
5.2 Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Application (2021-2026)
5.2.1 Global Chemotherapy-Induced Neutropenia Treatment Sales Forecast by Application (2021-2026)
5.2.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue Forecast by Application (2021-2026)
5.2.3 Global Chemotherapy-Induced Neutropenia Treatment Price Forecast by Application (2021-2026)
6 North America
6.1 North America Chemotherapy-Induced Neutropenia Treatment by Country
6.1.1 North America Chemotherapy-Induced Neutropenia Treatment Sales by Country
6.1.2 North America Chemotherapy-Induced Neutropenia Treatment Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Type
6.3 North America Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Application
7 Europe
7.1 Europe Chemotherapy-Induced Neutropenia Treatment by Country
7.1.1 Europe Chemotherapy-Induced Neutropenia Treatment Sales by Country
7.1.2 Europe Chemotherapy-Induced Neutropenia Treatment Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Type
7.3 Europe Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Chemotherapy-Induced Neutropenia Treatment by Region
8.1.1 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales by Region
8.1.2 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Type
8.3 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Application
9 Latin America
9.1 Latin America Chemotherapy-Induced Neutropenia Treatment by Country
9.1.1 Latin America Chemotherapy-Induced Neutropenia Treatment Sales by Country
9.1.2 Latin America Chemotherapy-Induced Neutropenia Treatment Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Type
9.3 Central & South America Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment by Country
10.1.1 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales by Country
10.1.2 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Type
10.3 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Application
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description and Business Overview
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Chemotherapy-Induced Neutropenia Treatment Products Offered
11.1.5 Amgen Related Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Description and Business Overview
11.2.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Sanofi Chemotherapy-Induced Neutropenia Treatment Products Offered
11.2.5 Sanofi Related Developments
11.3 Novartis AG
11.3.1 Novartis AG Corporation Information
11.3.2 Novartis AG Description and Business Overview
11.3.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Novartis AG Chemotherapy-Induced Neutropenia Treatment Products Offered
11.3.5 Novartis AG Related Developments
11.4 Baxter International
11.4.1 Baxter International Corporation Information
11.4.2 Baxter International Description and Business Overview
11.4.3 Baxter International Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Baxter International Chemotherapy-Induced Neutropenia Treatment Products Offered
11.4.5 Baxter International Related Developments
11.5 Teva Pharmaceuticals Industries
11.5.1 Teva Pharmaceuticals Industries Corporation Information
11.5.2 Teva Pharmaceuticals Industries Description and Business Overview
11.5.3 Teva Pharmaceuticals Industries Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia Treatment Products Offered
11.5.5 Teva Pharmaceuticals Industries Related Developments
11.6 Apotex
11.6.1 Apotex Corporation Information
11.6.2 Apotex Description and Business Overview
11.6.3 Apotex Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Apotex Chemotherapy-Induced Neutropenia Treatment Products Offered
11.6.5 Apotex Related Developments
11.7 Dr. Reddy’s Laboratory
11.7.1 Dr. Reddy’s Laboratory Corporation Information
11.7.2 Dr. Reddy’s Laboratory Description and Business Overview
11.7.3 Dr. Reddy’s Laboratory Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia Treatment Products Offered
11.7.5 Dr. Reddy’s Laboratory Related Developments
11.8 Biogenomics Limited
11.8.1 Biogenomics Limited Corporation Information
11.8.2 Biogenomics Limited Description and Business Overview
11.8.3 Biogenomics Limited Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Biogenomics Limited Chemotherapy-Induced Neutropenia Treatment Products Offered
11.8.5 Biogenomics Limited Related Developments
11.9 Ligand Pharmaceuticals
11.9.1 Ligand Pharmaceuticals Corporation Information
11.9.2 Ligand Pharmaceuticals Description and Business Overview
11.9.3 Ligand Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia Treatment Products Offered
11.9.5 Ligand Pharmaceuticals Related Developments
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description and Business Overview
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Chemotherapy-Induced Neutropenia Treatment Products Offered
11.1.5 Amgen Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Chemotherapy-Induced Neutropenia Treatment Market Estimates and Projections by Region
12.1.1 Global Chemotherapy-Induced Neutropenia Treatment Sales Forecast by Regions 2021-2026
12.1.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue Forecast by Regions 2021-2026
12.2 North America Chemotherapy-Induced Neutropenia Treatment Market Size Forecast (2021-2026)
12.2.1 North America: Chemotherapy-Induced Neutropenia Treatment Sales Forecast (2021-2026)
12.2.2 North America: Chemotherapy-Induced Neutropenia Treatment Revenue Forecast (2021-2026)
12.2.3 North America: Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Country (2021-2026)
12.3 Europe Chemotherapy-Induced Neutropenia Treatment Market Size Forecast (2021-2026)
12.3.1 Europe: Chemotherapy-Induced Neutropenia Treatment Sales Forecast (2021-2026)
12.3.2 Europe: Chemotherapy-Induced Neutropenia Treatment Revenue Forecast (2021-2026)
12.3.3 Europe: Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Chemotherapy-Induced Neutropenia Treatment Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Chemotherapy-Induced Neutropenia Treatment Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Region (2021-2026)
12.5 Latin America Chemotherapy-Induced Neutropenia Treatment Market Size Forecast (2021-2026)
12.5.1 Latin America: Chemotherapy-Induced Neutropenia Treatment Sales Forecast (2021-2026)
12.5.2 Latin America: Chemotherapy-Induced Neutropenia Treatment Revenue Forecast (2021-2026)
12.5.3 Latin America: Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Chemotherapy-Induced Neutropenia Treatment Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Chemotherapy-Induced Neutropenia Treatment Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Chemotherapy-Induced Neutropenia Treatment Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Chemotherapy-Induced Neutropenia Treatment Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Chemotherapy-Induced Neutropenia Treatment Market Segments
Table 2. Ranking of Global Top Chemotherapy-Induced Neutropenia Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Chemotherapy-Induced Neutropenia Treatment Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Antibiotic Therapy
Table 5. Major Manufacturers of Colony-Stimulating Factor Therapy
Table 6. Major Manufacturers of Granulocyte Transfusion
Table 7. Major Manufacturers of Splenectomy Procedure
Table 8. Major Manufacturers of Others
Table 9. Global Chemotherapy-Induced Neutropenia Treatment Market Size Growth Rate by Application 2020-2026 (K Units)
Table 10. Global Chemotherapy-Induced Neutropenia Treatment Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 11. Global Chemotherapy-Induced Neutropenia Treatment Sales by Regions 2015-2020 (K Units)
Table 12. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Regions (2015-2020)
Table 13. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Chemotherapy-Induced Neutropenia Treatment Sales by Manufacturers (2015-2020) (K Units)
Table 15. Global Chemotherapy-Induced Neutropenia Treatment Sales Share by Manufacturers (2015-2020)
Table 16. Global Chemotherapy-Induced Neutropenia Treatment Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Chemotherapy-Induced Neutropenia Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy-Induced Neutropenia Treatment as of 2019)
Table 18. Chemotherapy-Induced Neutropenia Treatment Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Chemotherapy-Induced Neutropenia Treatment Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Chemotherapy-Induced Neutropenia Treatment Price (2015-2020) (USD/Unit)
Table 21. Chemotherapy-Induced Neutropenia Treatment Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Chemotherapy-Induced Neutropenia Treatment Product Type
Table 23. Date of International Manufacturers Enter into Chemotherapy-Induced Neutropenia Treatment Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Chemotherapy-Induced Neutropenia Treatment Sales by Type (2015-2020) (K Units)
Table 26. Global Chemotherapy-Induced Neutropenia Treatment Sales Share by Type (2015-2020)
Table 27. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Chemotherapy-Induced Neutropenia Treatment Revenue Share by Type (2015-2020)
Table 29. Chemotherapy-Induced Neutropenia Treatment Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 30. Global Chemotherapy-Induced Neutropenia Treatment Sales by Application (2015-2020) (K Units)
Table 31. Global Chemotherapy-Induced Neutropenia Treatment Sales Share by Application (2015-2020)
Table 32. North America Chemotherapy-Induced Neutropenia Treatment Sales by Country (2015-2020) (K Units)
Table 33. North America Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country (2015-2020)
Table 34. North America Chemotherapy-Induced Neutropenia Treatment Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Country (2015-2020)
Table 36. North America Chemotherapy-Induced Neutropenia Treatment Sales by Type (2015-2020) (K Units)
Table 37. North America Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type (2015-2020)
Table 38. North America Chemotherapy-Induced Neutropenia Treatment Sales by Application (2015-2020) (K Units)
Table 39. North America Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application (2015-2020)
Table 40. Europe Chemotherapy-Induced Neutropenia Treatment Sales by Country (2015-2020) (K Units)
Table 41. Europe Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country (2015-2020)
Table 42. Europe Chemotherapy-Induced Neutropenia Treatment Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Country (2015-2020)
Table 44. Europe Chemotherapy-Induced Neutropenia Treatment Sales by Type (2015-2020) (K Units)
Table 45. Europe Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type (2015-2020)
Table 46. Europe Chemotherapy-Induced Neutropenia Treatment Sales by Application (2015-2020) (K Units)
Table 47. Europe Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales by Region (2015-2020) (K Units)
Table 49. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales by Type (2015-2020) (K Units)
Table 53. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales by Application (2015-2020) (K Units)
Table 55. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application (2015-2020)
Table 56. Latin America Chemotherapy-Induced Neutropenia Treatment Sales by Country (2015-2020) (K Units)
Table 57. Latin America Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Chemotherapy-Induced Neutropenia Treatment Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Country (2015-2020)
Table 60. Latin America Chemotherapy-Induced Neutropenia Treatment Sales by Type (2015-2020) (K Units)
Table 61. Latin America Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type (2015-2020)
Table 62. Latin America Chemotherapy-Induced Neutropenia Treatment Sales by Application (2015-2020) (K Units)
Table 63. Latin America Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales by Country (2015-2020) (K Units)
Table 65. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales by Type (2015-2020) (K Units)
Table 69. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales by Application (2015-2020) (K Units)
Table 71. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application (2015-2020)
Table 72. Amgen Corporation Information
Table 73. Amgen Description and Major Businesses
Table 74. Amgen Chemotherapy-Induced Neutropenia Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 75. Amgen Product
Table 76. Amgen Recent Development
Table 77. Sanofi Corporation Information
Table 78. Sanofi Description and Major Businesses
Table 79. Sanofi Chemotherapy-Induced Neutropenia Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Sanofi Product
Table 81. Sanofi Recent Development
Table 82. Novartis AG Corporation Information
Table 83. Novartis AG Description and Major Businesses
Table 84. Novartis AG Chemotherapy-Induced Neutropenia Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Novartis AG Product
Table 86. Novartis AG Recent Development
Table 87. Baxter International Corporation Information
Table 88. Baxter International Description and Major Businesses
Table 89. Baxter International Chemotherapy-Induced Neutropenia Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Baxter International Product
Table 91. Baxter International Recent Development
Table 92. Teva Pharmaceuticals Industries Corporation Information
Table 93. Teva Pharmaceuticals Industries Description and Major Businesses
Table 94. Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Teva Pharmaceuticals Industries Product
Table 96. Teva Pharmaceuticals Industries Recent Development
Table 97. Apotex Corporation Information
Table 98. Apotex Description and Major Businesses
Table 99. Apotex Chemotherapy-Induced Neutropenia Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Apotex Product
Table 101. Apotex Recent Development
Table 102. Dr. Reddy’s Laboratory Corporation Information
Table 103. Dr. Reddy’s Laboratory Description and Major Businesses
Table 104. Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Dr. Reddy’s Laboratory Product
Table 106. Dr. Reddy’s Laboratory Recent Development
Table 107. Biogenomics Limited Corporation Information
Table 108. Biogenomics Limited Description and Major Businesses
Table 109. Biogenomics Limited Chemotherapy-Induced Neutropenia Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. Biogenomics Limited Product
Table 111. Biogenomics Limited Recent Development
Table 112. Ligand Pharmaceuticals Corporation Information
Table 113. Ligand Pharmaceuticals Description and Major Businesses
Table 114. Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 115. Ligand Pharmaceuticals Product
Table 116. Ligand Pharmaceuticals Recent Development
Table 117. Global Chemotherapy-Induced Neutropenia Treatment Sales Forecast by Regions (2021-2026) (K Units)
Table 118. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share Forecast by Regions (2021-2026)
Table 119. Global Chemotherapy-Induced Neutropenia Treatment Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 120. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share Forecast by Regions (2021-2026)
Table 121. North America: Chemotherapy-Induced Neutropenia Treatment Sales Forecast by Country (2021-2026) (K Units)
Table 122. North America: Chemotherapy-Induced Neutropenia Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 123. Europe: Chemotherapy-Induced Neutropenia Treatment Sales Forecast by Country (2021-2026) (K Units)
Table 124. Europe: Chemotherapy-Induced Neutropenia Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 125. Asia Pacific: Chemotherapy-Induced Neutropenia Treatment Sales Forecast by Region (2021-2026) (K Units)
Table 126. Asia Pacific: Chemotherapy-Induced Neutropenia Treatment Revenue Forecast by Region (2021-2026) (US$ Million)
Table 127. Latin America: Chemotherapy-Induced Neutropenia Treatment Sales Forecast by Country (2021-2026) (K Units)
Table 128. Latin America: Chemotherapy-Induced Neutropenia Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 129. Middle East and Africa: Chemotherapy-Induced Neutropenia Treatment Sales Forecast by Country (2021-2026) (K Units)
Table 130. Middle East and Africa: Chemotherapy-Induced Neutropenia Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 131. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 132. Key Challenges
Table 133. Market Risks
Table 134. Main Points Interviewed from Key Chemotherapy-Induced Neutropenia Treatment Players
Table 135. Chemotherapy-Induced Neutropenia Treatment Customers List
Table 136. Chemotherapy-Induced Neutropenia Treatment Distributors List
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Chemotherapy-Induced Neutropenia Treatment Product Picture
Figure 2. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type in 2020 & 2026
Figure 3. Antibiotic Therapy Product Picture
Figure 4. Colony-Stimulating Factor Therapy Product Picture
Figure 5. Granulocyte Transfusion Product Picture
Figure 6. Splenectomy Procedure Product Picture
Figure 7. Others Product Picture
Figure 8. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application in 2020 & 2026
Figure 9. Hospitals
Figure 10. Ambulatory Surgical Center
Figure 11. Diagnostic Centers
Figure 12. Chemotherapy-Induced Neutropenia Treatment Report Years Considered
Figure 13. Global Chemotherapy-Induced Neutropenia Treatment Market Size 2015-2026 (US$ Million)
Figure 14. Global Chemotherapy-Induced Neutropenia Treatment Sales 2015-2026 (K Units)
Figure 15. Global Chemotherapy-Induced Neutropenia Treatment Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Region (2015-2020)
Figure 17. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Region in 2019
Figure 18. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Region (2015-2020)
Figure 19. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Region in 2019
Figure 20. Global Chemotherapy-Induced Neutropenia Treatment Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Chemotherapy-Induced Neutropenia Treatment Revenue in 2019
Figure 22. Chemotherapy-Induced Neutropenia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type (2015-2020)
Figure 24. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type in 2019
Figure 25. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Type (2015-2020)
Figure 26. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Type in 2019
Figure 27. Global Chemotherapy-Induced Neutropenia Treatment Market Share by Price Range (2015-2020)
Figure 28. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application (2015-2020)
Figure 29. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application in 2019
Figure 30. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Application (2015-2020)
Figure 31. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Application in 2019
Figure 32. North America Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate 2015-2020 (K Units)
Figure 33. North America Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country in 2019
Figure 35. North America Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Country in 2019
Figure 36. U.S. Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 37. U.S. Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 39. Canada Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Chemotherapy-Induced Neutropenia Treatment Market Share by Type in 2019
Figure 41. North America Chemotherapy-Induced Neutropenia Treatment Market Share by Application in 2019
Figure 42. Europe Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate 2015-2020 (K Units)
Figure 43. Europe Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country in 2019
Figure 45. Europe Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Country in 2019
Figure 46. Germany Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 47. Germany Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 49. France Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 51. U.K. Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 53. Italy Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 55. Russia Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Chemotherapy-Induced Neutropenia Treatment Market Share by Type in 2019
Figure 57. Europe Chemotherapy-Induced Neutropenia Treatment Market Share by Application in 2019
Figure 58. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate 2015-2020 (K Units)
Figure 59. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Region in 2019
Figure 61. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Region in 2019
Figure 62. China Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 63. China Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 65. Japan Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 67. South Korea Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 69. India Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 71. Australia Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 73. Taiwan Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 75. Indonesia Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 77. Thailand Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 79. Malaysia Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 81. Philippines Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 83. Vietnam Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Market Share by Type in 2019
Figure 85. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Market Share by Application in 2019
Figure 86. Latin America Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate 2015-2020 (K Units)
Figure 87. Latin America Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country in 2019
Figure 89. Latin America Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Country in 2019
Figure 90. Mexico Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 91. Mexico Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 93. Brazil Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 95. Argentina Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Chemotherapy-Induced Neutropenia Treatment Market Share by Type in 2019
Figure 97. Latin America Chemotherapy-Induced Neutropenia Treatment Market Share by Application in 2019
Figure 98. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate 2015-2020 (K Units)
Figure 99. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Country in 2019
Figure 102. Turkey Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 103. Turkey Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 105. Saudi Arabia Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate (2015-2020) (K Units)
Figure 107. U.A.E Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Market Share by Type in 2019
Figure 109. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Market Share by Application in 2019
Figure 110. North America Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. North America Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Europe Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Latin America Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 119. Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
化学療法誘発性好中球減少症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Chemotherapy Induced Neutropenia Drug Market The global Chemotherapy Induced Neutropenia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Chemotherapy Induced Neutropenia Drug S…- 化学療法薬誘発性肢端紅斑（手足症候群）治療の世界市場（～2026年） Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear afte…
- 化学療法誘発性貧血（CIA）の世界市場（～2026年） Anaemia is a frequent complication of malignancy and is aggravated by chemotherapy. The key factor contributing to the growth of the global chemotherapy induced anemia market is the increase in the occurrence of cancer and anemia among geriatric patients. Market Analysis and Insights: Global Chemoth…
- 化学療法誘発性悪心・嘔吐（CINV）の世界市場（～2026年） Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides…
- 化学療法誘発性悪心・嘔吐（CINV）治療薬の世界市場（～2026年） Market Analysis and Insights: Global Chemotherapy Induced Nausea and Vomiting （CINV） Drugs Market The global Chemotherapy Induced Nausea and Vomiting （CINV） Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Chemoth…